Duncker Streett & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-6,500
| Closed | -$25K | – | 563 |
|
|
2020
Q1 | $25K | Hold |
6,500
| – | – | 0.01% | 375 |
|
|
2019
Q4 | $33K | Buy |
+6,500
| New | +$34.4K | 0.01% | 386 |
|
|
2019
Q3 | – | Sell |
-7,500
| Closed | -$46K | – | 551 |
|
|
2019
Q2 | $46K | Sell |
7,500
-5,118
| -41% | -$24.7K | 0.01% | 370 |
|
|
2019
Q1 | $59K | Hold |
12,618
| – | – | 0.01% | 359 |
|
|
2018
Q4 | $53K | Sell |
12,618
-3,100
| -20% | -$15.8K | 0.01% | 355 |
|
|
2018
Q3 | $99K | Hold |
15,718
| – | – | 0.02% | 321 |
|
|
2018
Q2 | $126K | Hold |
15,718
| – | – | 0.03% | 289 |
|
|
2018
Q1 | $117K | Buy |
15,718
+1,000
| +7% | +$6.65K | 0.03% | 297 |
|
|
2017
Q4 | $88K | Hold |
14,718
| – | – | 0.02% | 344 |
|
|
2017
Q3 | $108K | Hold |
14,718
| – | – | 0.03% | 301 |
|
|
2017
Q2 | $100K | Hold |
14,718
| – | – | 0.03% | 314 |
|
|
2017
Q1 | $139K | Hold |
14,718
| – | – | 0.04% | 278 |
|
|
2016
Q4 | $127K | Hold |
14,718
| – | – | 0.04% | 278 |
|
|
2016
Q3 | $93K | Sell |
14,718
-2,000
| -12% | -$12.1K | 0.03% | 302 |
|
|
2016
Q2 | $71K | Hold |
16,718
| – | – | 0.03% | 317 |
|
|
2016
Q1 | $73K | Sell |
16,718
-2,000
| -11% | -$8.91K | 0.03% | 317 |
|
|
2015
Q4 | $115K | Sell |
18,718
-5,000
| -21% | -$32.8K | 0.04% | 277 |
|
|
2015
Q3 | $136K | Sell |
23,718
-1,500
| -6% | -$11.5K | 0.05% | 271 |
|
|
2015
Q2 | $188K | Hold |
25,218
| – | – | 0.07% | 249 |
|
|
2015
Q1 | $151K | Hold |
25,218
| – | – | 0.05% | 266 |
|
|
2014
Q4 | $191K | Hold |
25,218
| – | – | 0.06% | 247 |
|
|
2014
Q3 | $131K | Sell |
25,218
-6,500
| -20% | -$32.4K | 0.04% | 285 |
|
|
2014
Q2 | $137K | Buy |
31,718
+7,193
| +29% | +$27.5K | 0.04% | 293 |
|
|
2014
Q1 | $100K | Hold |
24,525
| – | – | 0.04% | 308 |
|
|
2013
Q4 | $131K | Hold |
24,525
| – | – | 0.05% | 280 |
|
|
2013
Q3 | $123K | Hold |
24,525
| – | – | 0.05% | 273 |
|
|
2013
Q2 | $109K | Buy |
+24,525
| New | +$110K | 0.04% | 283 |
|
Other funds holding PGNX
Duncker Streett & Co's PGNX Position: Q2 2020 in Review
Duncker Streett & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 6,500 shares — an estimated $25K sold.
Duncker Streett & Co first reported a position in PGNX in Q2 2013 and held it in 27 quarters. The position peaked at $191K in Q4 2014. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Duncker Streett & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Duncker Streett & Co sold 6,500 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $25K.
- Duncker Streett & Co first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 27 quarters.
- Duncker Streett & Co's Progenics Pharmaceuticals Inc position peaked at $191K in Q4 2014.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Duncker Streett & Co's 13F filing for Q2 2020, filed 22 Jul 2020.